Related Experiment Videos
Estrogen-progestin replacement therapy and endometrial cancer
M C Pike1, R K Peters, W Cozen
1Department of Preventive Medicine, USC/Norris Comprehensive Cancer Center, Los Angeles, CA 90033-0800, USA.
Journal of the National Cancer Institute
|August 6, 1997
Summary
To reduce endometrial cancer risk from estrogen therapy, use progestin for at least 10 days monthly in sequential therapy or use continuous combined therapy. Both methods effectively mitigate increased risks associated with hormone replacement therapy.
Area of Science:
- Gynecology
- Oncology
- Endocrinology
Background:
- Estrogen replacement therapy (ERT) is known to increase endometrial cancer risk.
- Sequential and continuous combined hormone replacement therapies (HRT) aim to mitigate this risk.
- Optimal progestin duration in sequential HRT for endometrial cancer prevention is unclear.
Purpose of the Study:
- To evaluate the impact of sequential and continuous combined HRT on endometrial cancer risk.
- To determine the effect of varying progestin durations in sequential HRT.
Main Methods:
- Population-based case-control study.
- 833 cases and 791 controls, postmenopausal white women aged 50-74.
- Adjusted odds ratios (ORs) calculated for HRT types and risk factors.
Main Results:
- ERT use increased endometrial cancer risk (OR=2.17 per 5 years).
- Sequential HRT with <10 days progestin showed a reduced but still elevated risk (OR=1.87).
- Sequential HRT with ≥10 days progestin (OR=1.07) and continuous combined HRT (OR=1.07) showed no increased risk.
Conclusions:
- At least 10 days of progestin monthly is crucial for sequential HRT to negate endometrial cancer risk.
- Continuous combined HRT is similarly effective in preventing endometrial cancer risk.
- Endometrial sloughing duration may be key in determining risk reduction.